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Materials and Methods

Chemicals and Radiochemicals
The self-stabilized oligodeoxynucleotide ( Fig. 1) was synthesized, purified, and analyzed by the same methods as previously described (10) (11) (12) we have successfully separated n-i, n-2, and n-3 oligonucleotides from the intact (33-mer) compounds. Figure 2 illustrates the plasma concentration-time course of the self-stabilized oligonucleotide equivalents after intravenous bolus administration of 35S-labeled self-stabilized oligonucleotide to rats. Pharmacokinetic analysis revealed that plasma disappearance curves for self-stabilized oligonucleotide-derived radioactivity could be described by the sum of two exponentials, with half-lives of 0.54 and 41.44 h ( Table 1 ). The chemical form of radioactivity in plasma was further evaluated by gel electrophoresis (Fig. 3) and HPLC (Fig. 4) , demonstrating the presence of intact self-stabilized oligonucleotide as well as minor metabolites with lower molecular masses.
Results
Kinetics and In Vivo Stability of Self-Stabilized Oligonucleotide in Plasma
Elimination of Self-Stabilized
Ohigonucleotide through
Urine and Feces Figure 5 shows Plasma concentrations are expressed as self-stabilized oligonucleotide equivalents, mg/L (mean ± SD), after intravenous bolus administration at 30 mg/kg. Three animals were used for each time point. Pharmacokinetic analysis of the plasma disappearance curves for self-stabilized oligonucleotide-derived radioactivity described the curves as the sum of two exponentials, with half-lives of 0.54 and 4144 h (see Table 1 ).
240 h. All the radioactivity in urine was present as degradative products of self-stabilized oligonucleotide, as analyzed by HPLC (Fig. 6) . Fecal excretion was a minor pathway of elimination of self-stabilized oligonucleotide with 2.46% ± 0.61% of the administered dose being excreted in 24 hand 8.65% ± 2.19% within 240 h. As with urine, all the radioactivity in feces was present as degradative products of self-stabilized oligonucleotide (data not shown). Figure 7 illustrates the self-stabilized oligonucleotide-equivalent concentrations of radioactivity in tissues after intravenous bolus administration of 35S-labeled self-stabilized oligonucleotide into rats. The results indicate that the self-stabilized oligonucleotide had a wide tissue distribution.
Distribution and Stability of Self-Stabilized Ohigonucleotide in Various Tissues
Kidney.
The self-stabilized oligonucleotide-derived radioactivity was detected in kidneys within 5 mm after administration of the oligonucleotide, peaked between 6-18 h, and remained high in concentration thereafter, being 10-100-fold higher than that of plasma throughout the rest of the experimental period (Fig. 7A) . Gel-electrophoretic analysis demonstrated that the majority of the radioactivity was associated to intact self-stabilized oligonucleotide and that some metabolites were present in the kidneys (Fig. 8, top) . Enterohepatic system. Throughout the experimental period a high concentration of radioactivity persisted in the liver, with the highest concentration occurring between 3 and 6 h (Fig. 7B) . Gel-electrophoretic analysis indicated that mainly the intact form of selfstabilized oligonucleotide and minor degradative metabolites were present in the liver (Fig. 8, middle) a Means based on the experimental data from 30 rats after administration of S-Iabeled ollgonucleotide (30mg/kg). b concentrations in various tissues were based on the quantitation of radioactivity. C,,., maximum concentration; AuC, area under the curve (mg/L) x h; MAT, mean residue time; CL, clearance rate, mL/kg per hour.
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After Administration a. for 2 h at 37CCwere then extracted twice with phenol:chtoroforrn (1:1. by vol) and once with chloroform. After ethanol precipitation, the oligonucleotides were analyzed by PAGE. The gel was fixed and dried before autoradlography. 
7B), mainly as the intact form (data not shown).
Spleen. Radioactivity in the spleen was observed throughout the experimental period, the highest concentration being seen between 5 and 30 mm and decreased amounts thereafter (Fig. 7A) .
Heart.
Radioactivity in the heart was detected within 5 mm, with the highest concentrations observed between 15 and 30 mm (Fig. 7A) . The concentration in the heart then decreased and was similar to the corresponding amount in plasma throughout the remainder of the experimental period.
Lungs.
Throughout the experimental period, radioactivity was detected in the lungs at concentrations exceeding that observed in plasma 6 h after dosing (Fig. 7A) .
Bone marrow.
The self-stabilized oligonucleotide-derived radioactivity was observed in the bone marrow (Fig. 7A) . After 6 h, the concentrations in bone marrow present at a low concentration throughout the experimental period (Fig. 7C) .
Thyroid.
The self-stabilized oligonucleotide-derived radioactivity was observed in the thyroid, with the highest concentrations observed between 15 and 60 mm (Fig. 7C) . The concentration of radioactivity in thyroid remained 5-20-fold higher than that of plasma throughout the rest of the experimental period. Other tissues. The self-stabilized oligonucleotide-derived radioactivity was observed in the adrenal (Fig.  7C) , and at low concentrations in skeletal muscle (Fig.   7D ), skin (Fig. 7D) , thymus (Fig. 7C) , testes (Fig. 7D) , and fat (Fig. 7D) . Except for that in the adrenal, the concentrations were the same or lower than the corresponding plasma value within 6 h after dosing, but greater than the corresponding plasma concentrations thereafter.
In Vivo Metabolism of Self-Stabilized Oligonucleotide
The chemical forms of radioactivity were examined by PAGE and HPLC. As illustrated in Fig. 3 , both intact self-stabilized oligonucleotide and its metabolites were detected in plasma, being present mainly in the intact form at 6 h after dosing. Intact self-stabilized oligonucleotide was still detectable in plasma up to 12 h, indicating that the self-stabilized oligonucleotide is relatively stable in vivo. Intact self-stabilized oligonucleotide was also detectable by PAGE in several tissues for a longer period, including kidney, liver, and intestine (Fig. 8) . Similar results were obtained by HPLC analysis.
Although the tissue distribution pattern of radioactivity was similar to that of GEM 91, the majority of radioactivity in tissues was associated with the parent form, indicating that the self-stabilized oligonucleotide is more stable than GEM 91 in vivo (8) .
Pharmacokinetic Analysis
From the experimental data on determining radioactivity in biological fluids and tissues, we calculated pharmacokinetic parameters for the self-stabilized oligonucleotide in each tissue and biological fluids by using computer-based two-compartmental intravenous bolus or absorption models. Table 1 Initially, the self-stabilized oligonucleotide was distributed mainly in highly perfused tissues, including the liver, kidneys, heart, lungs, and spleen. The prolonged elimination phase reflected retention of self-stabilized oligonucleotide (and possibly its metabolites) in several tissues, especially the kidney, liver, lung, heart, bone marrow, and intestine. In the present study, urinary excretion represents the major route of elimination of self-stabilized oligonucleotide-derived radioactivity, similar to what was seen with GEM 91 (8) . Urinary excretion of selfstabilized oligonucleotide-derived radioactivity occurred mainly in the first 48 h (-40%).
Over the next 8 days, 3-5% of the administered dose was excreted into urine each day. Closer examination of the HPLC profile (Fig. 6) ).
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Standard 5mm 30mm lh 3h 6h 12h were relatively high in bone marrow, heart, lung, spleen, adrenal, and thyroid tissue. In particular, the radioactivity in these tissues was consistently higher than the corresponding plasma values during the elimination phase of the self-stabilized oligonucleotide.
As shown in Tables 1 and 2 , for most tissues and biological fluids, the half-lives of the elimination phase of self-stabilized oligonucleotide-derived radioactivity were significantly longer than that observed in plasma. More importantly, this self-stabilized oligonucleotide was more stable in various tissues than the other oligonucleotide phosphorothioates examined previously
(5-8).
This may indicate an accumulation of oligonucleotide in those tissues possibly related to therapeutic effects. In general, PAGE analysis of the extracted radioactivity from plasma ( Fig. 3 ), kidney and liver (Fig. 8) , and various other tissues (data not shown) showed that majority of the radioactivity was associated with the intact oligonucleotide; however, some 32-mer, 31-mer, and shorter lengths were also present.
In 
